A randomized comparison of comprehensive weight loss intervention vs. usual care on recurrences of atrial fibrillation in obese patients after catheter ablation: HOBIT-AF trial
EP Europace Journal

Abstract
Obesity is one of the strongest risk factors for the development of atrial fibrillation (AF), and its reduction is associated with the alleviation of AF burden. The HOBIT-AF study aimed to evaluate the impact of complex weight loss interventions on AF recurrence rate in obese individuals after catheter ablation (CA).
The HOBIT-AF was a randomized controlled trial with a 15-month treatment period (3–18 months post CA) involving complex weight-reducing interventions in the active arm. The primary outcome was the change in AF/atrial tachycardia (AT) burden assessed from baseline and the final 14-day Holter monitoring. A total of 167 individuals (aged 59 years, body mass index of 35.6 kg/m2) were randomized into the active (
HOBIT-AF trial showed that despite the beneficial effect of body weight reduction on metabolic profile of obese patients with predominantly paroxysmal AF after CA, no reduction in AF/AT recurrence was observed in comparison with control patients. This may be likely due to low AF burden after previous CA, limiting further improvement.
Contributors

Kristýna Koščálová
Author

née Štolbová
Author

Peter Novodvorský
Author

Iva Jakubíková
Author

Adam Ševčík
Author

Adam Rafaj
Author

Iveta Pleyerová
Author

Kristýna Heidu
Author

Jakub Štoček
Author

Helena Kratochvílová
Author

Luděk Horváth
Author

Miloš Mráz
Author

Jan Mareš
Author

Dan Wichterle
Author
You may be interested in





